momelotinib dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: momelotinib dihydrochloride
• 英文别名: N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride；Momelotinib hydrochloride；N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;hydrochloride
• 化学式: C₂₃H₂₂N₆O₂*2ClH
• 分子量: 487.389
• InChiKey: NGOUSYFDVUVHDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  momelotinib dihydrochloride 在 sodium carbonate 作用下， 以 水 为溶剂， 以300 mg的产率得到莫洛替尼
  参考文献：
  名称：

  [EN] SOLID FORMS OF MOMELOTINIB SALTS AND IMPROVED PROCESSES FOR THE PREPARATION OF MOMELOTINIB
  [FR] FORMES SOLIDES DE SELS DE MOMÉLOTINIB ET PROCÉDÉS AMÉLIORÉS POUR LA PRÉPARATION DE MOMÉLOTINIB

  摘要：

  The present invention relates to the Amorphous Solid Dispersions (ASDs) of Momelotinib di-hydrochloride and processes for preparation thereof. Compared to a crystalline form, a stable amorphous form of Momelotinib di-hydrochloride enhances the solubility of the drug. The stable amorphous solid dispersions of Momelotinib di- hydrochloride reported herein can be easily reproduced and are amenable for processing into a dosage form. The present invention further provides processes for preparing Momelotinib salts and their use as means to purify the free base. Further, the process of preparation of Momelotinib free base via the neutralization of certain salt forms of Momelotinib significantly improves the chemical purity of the free base.

  公开号：

  WO2023152773A1
• 作为产物：
  描述：

  莫洛替尼 在 盐酸 作用下， 以 甲醇 、 异丙醇 为溶剂， 以1.4 g的产率得到momelotinib dihydrochloride
  参考文献：
  名称：

  [EN] SOLID FORMS OF MOMELOTINIB SALTS AND IMPROVED PROCESSES FOR THE PREPARATION OF MOMELOTINIB
  [FR] FORMES SOLIDES DE SELS DE MOMÉLOTINIB ET PROCÉDÉS AMÉLIORÉS POUR LA PRÉPARATION DE MOMÉLOTINIB

  摘要：

  The present invention relates to the Amorphous Solid Dispersions (ASDs) of Momelotinib di-hydrochloride and processes for preparation thereof. Compared to a crystalline form, a stable amorphous form of Momelotinib di-hydrochloride enhances the solubility of the drug. The stable amorphous solid dispersions of Momelotinib di- hydrochloride reported herein can be easily reproduced and are amenable for processing into a dosage form. The present invention further provides processes for preparing Momelotinib salts and their use as means to purify the free base. Further, the process of preparation of Momelotinib free base via the neutralization of certain salt forms of Momelotinib significantly improves the chemical purity of the free base.

  公开号：

  WO2023152773A1

文献信息

• (N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
  申请人：Gilead Sciences, Inc.

  公开号：US20150361050A1

  公开（公告）日：2015-12-17

  The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

  本发明涉及N-(氰甲基)-4-(2-(4-吗啉基苯氨基)嘧啶-4-基)苯甲酰的稳定新盐形式，适用于制备药物配方，并用于治疗。
• PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Burns Christopher John

  公开号：US20100197671A1

  公开（公告）日：2010-08-05

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及苯基氨基嘧啶化合物，它们是蛋白激酶抑制剂，包括JAK激酶。特别是，这些化合物对JAK2激酶具有选择性。这些激酶抑制剂可用于治疗与激酶相关的疾病，如免疫和炎症性疾病，包括器官移植；增生性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE HYDROCHLORIDE SALTS
  申请人：Gilead Sciences, Inc.

  公开号：EP3154950A1

  公开（公告）日：2017-04-19
• Phenyl Amino Pyrimidine Compounds and Uses Thereof
  申请人：Sierra Oncology, Inc.

  公开号：US20220388967A1

  公开（公告）日：2022-12-08

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
• US8486941B2
  申请人：——

  公开号：US8486941B2

  公开（公告）日：2013-07-16